Listen on the go
CORRECT!
Next question
touchONCOLOGY touchONCOLOGY
    • FILTER YOUR SEARCH
    Content Type:
    Speciality:
    More Specialities
    Conference:
    More Conferences

    • COVID-19

    An Introduction to COVID-19

    On 11 March 2020, the World Health Organization declared COVID-19 a global pandemic. The impact on the medical community has been huge, not only on the front line of medical care but also for those navigating patient treatment during this unprecedented situation.

    The touchONCOLOGY expert faculty have been sharing their experiences and advice during this challenging time through video interviews and short articles.

    COVID-19 Content

    COVID-19
    SARS-CoV-2 mRNA vaccination associated with increased survival in patients with lung cancer and melanoma treated with immune checkpoint inhibitors

    The COVID-19 pandemic accelerated the development of mRNA technologies, most notably with the creation of mRNA vaccines targeting SARS-CoV-2. While these vaccines helped control the pandemic, their potential may extend beyond infectious diseases, with growing interest in their potential application to cancer immunotherapy. At the European Society for Medical Oncology (ESMO) annual meeting in September […]

    COVID-19, Paediatric Oncology
    Developed by Touch
    Pamela Kearns: Leading SIOP Europe during the COVID-19 Pandemic
    Watch Time: 3 mins

    touchONCOLOGY spoke to Professor Pamela Kearns (University of Birmingham, UK) to discuss her experience as President of SIOP Europe during the COVID-19 pandemic, and the biggest achievements of the European paediatric oncology community during that time. Questions How would you describe your experience as the SIOP Europe President (2019–21) and how the COVID-19 pandemic influenced […]

    COVID-19
    COVID Coagulopathy and Thrombosis: A Systematic Review
    Roshan Asrani, Wadie F Bahou

    touchREVIEWS in Oncology & Haematology. 2022;18(1):78–87 DOI: https://doi.org/10.17925/OHR.2022.18.1.78

    In December 2019, an outbreak of pneumonia of unknown aetiology was observed in the Chinese city of Wuhan, capital of Hubei province. By January 2020, this outbreak was attributed to a novel virus classified as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the latest member of the coronaviridae family responsible for major infectious outbreaks, including […]

    COVID-19, Genitourinary Cancer
    Morgan Rouprêt
    Developed by Touch
    Morgan Rouprêt, ESOU22: What Have We Learned From the COVID-19 Pandemic?
    Watch Time: 6 mins

    touchONCOLOGY are joined by the EAU Section of Oncological Urology (ESOU) Chairman Professor Morgan Rouprêt to discuss what we have learned from the COVID-19 pandemic, how this has impacted the care of cancer patients and what we can do to move forward. Questions       What was the impact of the COVID-19 pandemic on […]

    COVID-19
    Mark Lawler, European Cancer Summit 2021: Time To Act: COVID-19 & Cancer Campaign

    We were delighted to catch up with Prof Mark Lawler to discuss the challenges that the COVID-19 pandemic has had on cancer care in Europe, and the key objectives and messages of the Time To Act: COVID-19 & Cancer campaign. Questions 1. What has been the impact of the COVID-19 pandemic on cancer screening and […]

    COVID-19
    Scott Shepherd, ESMO 2021: The CAPTURE Study: Adaptive Immunity to SARS-CoV-2 Infection and Vaccination in Cancer Patients (Part Two)

    touchONCOLOGY joins Dr Scott Shepherd (London, UK), to discuss his presentation at ESMO 2021 on the CAPTURE study exploring adaptive immunity to SARS-CoV-2 infection and vaccination in cancer patients. To view Part One click here. Questions 1. How did immune responses relate to cancer stage and disease status? (00:18-03:26) 2. What are the implications of […]

    COVID-19
    Scott Shepherd, ESMO 2021: The CAPTURE Study: Adaptive Immunity to SARS-CoV-2 Infection and Vaccination in Cancer Patients (Part One)

    touchONCOLOGY joins Dr Scott Shepherd (London, UK), to discuss his presentation at ESMO 2021 on the CAPTURE study exploring adaptive immunity to SARS-CoV-2 infection and vaccination in cancer patients. To view Part Two click here. Questions 1. What were the aims and design of the CAPTURE study? (00:18-02:25) 2. What were the study findings in […]

    COVID-19
    Markus Joerger, ESMO 2021: Final Results of SAKK 80/20 – COVID-19 Infection in Cancer Patients

    touchONCOLOGY joins Dr Markus Joerger (St. Gallen Cancer Center, Switzerland) at ESMO 2021 to discuss the outcome and prognostic factors of COVID-19 infection in cancer patients. Questions 1. What were the objectives of the SAKK 80/20 study? (00:15-00:50) 2. Could you give us a brief overview of the patient population of this study? (00:50-02:14) 3. […]

    COVID-19
    Onc 3_T.png
    COVID-19 Vaccination in Patients with Chronic Lymphocytic Leukaemia: What Can We Expect?
    Mohammad Ammad Ud Din, Saad Jamshed

    touchREVIEWS in Oncology & Haematology. 2021;17(1):7-8 DOI: https://doi.org/10.17925/OHR.2021.17.1.7

    Advanced age and other comorbid conditions put patients with chronic lymphocytic leukaemia (CLL) at an increased risk of morbidity and mortality from SARS-CoV-2 infection, with early studies showing case fatality rates of over 30% in patients with CLL with symptomatic COVID-19.1,2 As the vaccination against COVID-19 is becoming available for use in the general population, its […]

    In Partnership with...
    Useful Links:
    About us Society Partners Press Releases Contact Us Permissions Terms & Conditions Privacy Policy Cookie Preferences
    Connect With Us:

    Other websites from Touch Medical Media:

    touchONCOLOGY
    touchOPHTHALMOLOGY
    touchENDOCRINOLOGY
    touchNEUROLOGY
    touchCARDIO
    touchRESPIRATORY
    touchIMMUNOLOGY
    touchINFECTIOUS DISEASES
    touchHAEMATOLOGY
    touchDERMATOLOGY

    Copyright® 2024 Touch Medical Media. Touch Medical Media Group Holdings Limited, a private limited company registered in England and Wales at 3 Stockport Exchange | Stockport | Cheshire | SK1 3GG | UK with registered number 08197142.

    touchONCOLOGY is for informational purposes and intended for healthcare professionals only. Its content should not be considered medical advice, diagnosis or treatment recommendations.

    Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72
    Close Popup